Desentum Oy. Desentum is a Finnish pharmaceutical development company (a spin-off from VTT) that is developing allergy immunotherapy using novel genetically modified allergens. The company’s goal is to improve the effectiveness and safety of allergy immunotherapy, as well as to make it faster and easier for patients.
The company’s drug development programs are targeted towards allergies that are highly prevalent or for which effective treatments are currently unavailable. The key allergies for the company are birch, grass, and peanut allergies. According to GlobalData’s estimate, there are over 200 million patients suffering from these allergies in the 16 largest pharmaceutical markets worldwide.
Among the company’s largest shareholders are VTT Ventures, Cascara Ventures (Adriaan Hart de Ruijter), Acme Investments (Timo Syrjälä), and Musta Aukko Oy (Pekka Mattila).
Investment in 2024.